Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam

Neoadjuvant Doxorubicin-Paclitaxel Combined Chemotherapy in Patients with Inoperable Stage III Breast Cancer: A Retrospective Cohort Study with 10 Years of Follow-Up in Vietnam

Abstract Introduction The combination of doxorubicin and paclitaxel (AP) is widely used in our country for the neoadjuvant treatment of breast cancer as well as metastatic breast cancer. The AP regimen has shown promise as a neoadjuvant therapy for breast cancer that improves pathological complete r...

Full description

Bibliographic Details
Main Authors: Duc Thanh Le, Lap Thanh Bui, Chu Van Nguyen, Kien Hung Do, Giang Le Tran, Tu Anh Do
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-06-01
Series:Oncology and Therapy
Subjects:
Doxorubicin-paclitaxel regimen
Advanced breast cancer
Neoadjuvant chemotherapy
Pathological complete response
Online Access:https://doi.org/10.1007/s40487-023-00233-8

Internet

https://doi.org/10.1007/s40487-023-00233-8

Similar Items